Research LetterHematologyOncology
Open Access | 
10.1172/jci.insight.203981
Clonal hematopoiesis in lung adenocarcinoma pathogenesis
Tiziana Parisi,1 Blanca Santibanez Ocampo,1 Jacob Adelman,1 Yuyan Cai,1 Marie McConkey,2 Christopher J. Gibson,2 Benjamin L. Ebert,2,3 Peter Miller,3,4 and Tyler Jacks1
1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
2Dana Farber Cancer Institute, Boston, Massachusetts, USA.
3Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
4Krantz Family Center for Cancer Research Massachusetts General Hospital, Boston, Massachusetts, USA.
Address correspondence to: Peter G. Miller, 185 Cambridge Street, CPZN 4100, Boston, MA 02114, USA. Email: pmiller4@mgb.org. Or to: Tyler Jacks, Koch Institute for Integrative Cancer Research at MIT, 77 Massachusetts Avenue; 76-453, Cambridge, MA 02139, USA. Email: tjacks@mit.edu.
Find articles by Parisi, T. in: PubMed | Google Scholar
1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
2Dana Farber Cancer Institute, Boston, Massachusetts, USA.
3Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
4Krantz Family Center for Cancer Research Massachusetts General Hospital, Boston, Massachusetts, USA.
Address correspondence to: Peter G. Miller, 185 Cambridge Street, CPZN 4100, Boston, MA 02114, USA. Email: pmiller4@mgb.org. Or to: Tyler Jacks, Koch Institute for Integrative Cancer Research at MIT, 77 Massachusetts Avenue; 76-453, Cambridge, MA 02139, USA. Email: tjacks@mit.edu.
Find articles by Santibanez Ocampo, B. in: PubMed | Google Scholar
1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
2Dana Farber Cancer Institute, Boston, Massachusetts, USA.
3Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
4Krantz Family Center for Cancer Research Massachusetts General Hospital, Boston, Massachusetts, USA.
Address correspondence to: Peter G. Miller, 185 Cambridge Street, CPZN 4100, Boston, MA 02114, USA. Email: pmiller4@mgb.org. Or to: Tyler Jacks, Koch Institute for Integrative Cancer Research at MIT, 77 Massachusetts Avenue; 76-453, Cambridge, MA 02139, USA. Email: tjacks@mit.edu.
Find articles by Adelman, J. in: PubMed | Google Scholar
1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
2Dana Farber Cancer Institute, Boston, Massachusetts, USA.
3Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
4Krantz Family Center for Cancer Research Massachusetts General Hospital, Boston, Massachusetts, USA.
Address correspondence to: Peter G. Miller, 185 Cambridge Street, CPZN 4100, Boston, MA 02114, USA. Email: pmiller4@mgb.org. Or to: Tyler Jacks, Koch Institute for Integrative Cancer Research at MIT, 77 Massachusetts Avenue; 76-453, Cambridge, MA 02139, USA. Email: tjacks@mit.edu.
Find articles by Cai, Y. in: PubMed | Google Scholar
1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
2Dana Farber Cancer Institute, Boston, Massachusetts, USA.
3Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
4Krantz Family Center for Cancer Research Massachusetts General Hospital, Boston, Massachusetts, USA.
Address correspondence to: Peter G. Miller, 185 Cambridge Street, CPZN 4100, Boston, MA 02114, USA. Email: pmiller4@mgb.org. Or to: Tyler Jacks, Koch Institute for Integrative Cancer Research at MIT, 77 Massachusetts Avenue; 76-453, Cambridge, MA 02139, USA. Email: tjacks@mit.edu.
Find articles by McConkey, M. in: PubMed | Google Scholar
1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
2Dana Farber Cancer Institute, Boston, Massachusetts, USA.
3Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
4Krantz Family Center for Cancer Research Massachusetts General Hospital, Boston, Massachusetts, USA.
Address correspondence to: Peter G. Miller, 185 Cambridge Street, CPZN 4100, Boston, MA 02114, USA. Email: pmiller4@mgb.org. Or to: Tyler Jacks, Koch Institute for Integrative Cancer Research at MIT, 77 Massachusetts Avenue; 76-453, Cambridge, MA 02139, USA. Email: tjacks@mit.edu.
Find articles by
Gibson, C.
in:
PubMed
|
Google Scholar
|
1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
2Dana Farber Cancer Institute, Boston, Massachusetts, USA.
3Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
4Krantz Family Center for Cancer Research Massachusetts General Hospital, Boston, Massachusetts, USA.
Address correspondence to: Peter G. Miller, 185 Cambridge Street, CPZN 4100, Boston, MA 02114, USA. Email: pmiller4@mgb.org. Or to: Tyler Jacks, Koch Institute for Integrative Cancer Research at MIT, 77 Massachusetts Avenue; 76-453, Cambridge, MA 02139, USA. Email: tjacks@mit.edu.
Find articles by
Ebert, B.
in:
PubMed
|
Google Scholar
|
1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
2Dana Farber Cancer Institute, Boston, Massachusetts, USA.
3Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
4Krantz Family Center for Cancer Research Massachusetts General Hospital, Boston, Massachusetts, USA.
Address correspondence to: Peter G. Miller, 185 Cambridge Street, CPZN 4100, Boston, MA 02114, USA. Email: pmiller4@mgb.org. Or to: Tyler Jacks, Koch Institute for Integrative Cancer Research at MIT, 77 Massachusetts Avenue; 76-453, Cambridge, MA 02139, USA. Email: tjacks@mit.edu.
Find articles by Miller, P. in: PubMed | Google Scholar
1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
2Dana Farber Cancer Institute, Boston, Massachusetts, USA.
3Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
4Krantz Family Center for Cancer Research Massachusetts General Hospital, Boston, Massachusetts, USA.
Address correspondence to: Peter G. Miller, 185 Cambridge Street, CPZN 4100, Boston, MA 02114, USA. Email: pmiller4@mgb.org. Or to: Tyler Jacks, Koch Institute for Integrative Cancer Research at MIT, 77 Massachusetts Avenue; 76-453, Cambridge, MA 02139, USA. Email: tjacks@mit.edu.
Find articles by Jacks, T. in: PubMed | Google Scholar
Published May 8, 2026 - More info
JCI Insight. 2026;11(9):e203981. https://doi.org/10.1172/jci.insight.203981.
© 2026 Miller et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Clonal hematopoiesis (CH) is an age-associated expansion of hematopoietic stem cells (HSC) clones harboring somatic mutations. Individuals with CH have higher mortality and increased risk of hematologic malignancies, cardiovascular disease, and inflammatory conditions, likely driven by aberrant inflammatory programs in mutant immune cells (1). For example, TET2 loss leads to exaggerated IL-1β and IL-6 responses after LPS exposure.
CH is enriched in individuals with solid tumors and correlates with higher mortality. However, whether mutant hematopoietic populations causally enhance tumor growth remains unclear. The relationship may be multifactorial, reflecting prior cytotoxic exposure and the immunomodulatory effects of CH-derived myeloid cells. In patients with CH and non–small cell lung cancer (NSCLC), mutant hematopoietic cells within tumor biopsies were recently shown to associate with worse cancer outcomes. Using a mouse model of CH and orthotopic NSCLC implantation, the authors found that CH altered tumor immune composition but did not report in vivo tumor growth phenotypes (2).
To define the effect of hematopoietic Tet2 loss on tumor development in vivo, we used congenic, autochthonous TET2-mutant CH mouse models combined with lung adenocarcinoma (LUAD) driven by inducible KrasG12D and Trp53 loss (KP mice). Whole bone marrow from Tet2fl/fl;Vav-Cre (Tet2 KO) or Tet2+/+;Vav-Cre (Tet2 WT) donors was transplanted into lethally irradiated KrasLSL-G12D/+;Trp53fl/fl (KP) recipients (Figure 1A). Tet2fl/fl;Vav-Cre induces hematopoietic Tet2 loss, while the KP system recapitulates LUAD development induced by intratracheal Adeno-Cre instillation (1, 3). Hematopoietic reconstitution was confirmed at 7 weeks, and tumors were induced with Adeno-Cre at 8 weeks.
Figure 1Effects of TET2-mutant CH on LUAD and immune cell repertoire. (A) Experimental approach. (B) Flow cytometry analyses of peripheral blood. Each dot represents a mouse (n = 11–24). (C) Tumor burden and grade at 16 weeks. Each dot represents a mouse (n = 30–32). (D) Images of lymphoid aggregates (LAs) in non-tumor bearing lungs. (E) IHC of lung from Tet2 KO mouse (top) and relative quantification within LAs. Each color represents data from a single mouse (n = 4–11). (F) IHC quantification of immune cells within tumors. Each color represents data from a single mouse (n = 9–11). Data are from 2 or 3 independent experiments at 16-week time point (color-coded in B and C). Circles represent color-coded means, and data are shown as mean ± SEM. Statistical analyses were performed with 1-way ANOVA tests (B, Tukey, E, Brown-Forsythe and Welch nested), in C with the Mann-Whitney U test, and in F with 2-tailed nested t test of nested. T, tumor. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Before tumor induction, Tet2-KO mice showed decreased peripheral B cells and increased T cells, monocytes, and neutrophils. By 16 weeks, only B cell differences remained significant (Figure 1B and Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.203981DS1). Splenic composition was also altered in tumor-bearing and non–tumor-bearing Tet2-KO mice, with more CD4+ and fewer CD8+ T cells and an increase in conventional DCs (cDCs, CD11c+MHCII+), skewed toward cDC2s over cDC1s (Supplemental Figure 1B).
Computed tomography and histopathology at 12 and 16 weeks showed no significant difference in tumor burden (tumor area per lung) or grade between Tet2 WT and -KO mice (Figure 1C and Supplemental Figure 1C). Instead, Tet2-KO mice exhibited increased pulmonary lymphoid aggregates (LA) (Figure 1, D and E, and Supplemental Figure 1, D and E). These resembled tertiary lymphoid structures (TLS), immune aggregates that modulate antitumor responses, including in NSCLC (4). LA numbers per lung were significantly higher in Tet2-KO mice with and without tumors than in WT (approximately 2- to 3-fold).
IHC analyses revealed distinct LAs and tumor microenvironment (TME) composition by hematopoietic genotype. In the absence of tumors, LAs in Tet2-KO mice contained more CD4+ and fewer Foxp3+ T cells, as well as fewer Ly6G+ myeloid cells, while trends observed in B cells and macrophages became significant in tumor-bearing lungs (Figure 1E). Of note, however, within the TME, only differences in macrophages and CD8+ T cells were significant in Tet2-KO versus WT mice (Figure 1F).
Together, these data show that Tet2-mutant hematopoiesis reshapes immune cell composition and LA abundance in the blood, spleen, lung parenchyma, and LUAD TME. LA number and composition depended on hematopoietic genotype and tumor presence, consistent with their role in antitumor immunity and checkpoint inhibitor response in lung cancer. Despite these immune alterations, LUAD burden and grade were unchanged, suggesting that Tet2-mutant hematopoiesis modulates the immune landscape without directly promoting tumor growth.
Our findings align partly with prior reports using orthotopic tumor implantation models of Tet2-mutant CH. One study reported a myeloid-enriched TME without changes in tumor burden, though LAs were not evaluated (2). Another study using myeloid-specific Tet2 deletion found increased tumor growth and more granulocytes in the TME but did not assess LAs (5). Differences in experimental design, timing, and tissue context likely explain these differences.
The KP model offers important advantages for studying LUAD initiation and progression in situ, but it also has limitations. Tumors driven by KrasG12D activation and Trp53 loss are aggressive and relatively nonantigenic, which may obscure subtle immune effects and limit the assessment of CH influence on metastatic potential. Bone marrow transplantation used to establish CH may also alter T cell repertoire and immune tone. Finally, our experiments did not incorporate cytotoxic or immunotherapeutic exposures, which are clinically relevant modifiers of CH biology and might reveal additional interplay between mutant hematopoietic cells and tumor immunity, as recently shown with TET2-mutant CH (6).
In summary, Tet2-mutant CH reshapes systemic and tissue-level immune architecture, including expansion of tertiary lymphoid-like structures, but it does not accelerate autochthonous LUAD progression in KP mice. These findings show that CH can reshape the tumor immune microenvironment without accelerating tumorigenesis, supporting future studies across CH genotypes, tumor models, and therapeutic contexts.
